NeuroCes
CRANIAL ELECTROTHERAPY STIMULATOR
DEPRESSION, ANXIETY AND INSOMNIA TREATMENT
NeuroCes™ reduces depression, anxiety and insomnia symptoms in a spectacular way with no significant side effects.
NeuroCes™ has been intended for professional and personal use
NeuroCes™ can be used in doctor’s offices, hospitals and clinics as well as at home and office without medical supervision.
NeuroCes™ is safe, effective, and simple to use.
NeuroCes™ is a battery operated portable medical device that is used for the FDA recognized treatment of anxiety, depression and insomnia via a process called Cranial Electrotherapy Stimulation (CES).
NeuroCes™ who draws advantages from the wealth of knowledge established over time has been designed to combine state-of-the-art technologies with advanced Cranial Electrotherapy Stimulation technique.
NeuroCes™ is a medical device that can also be used to treat symptoms of Depression, Anxiety and Insomnia that accompany conditions such as;
Anxiety Disorders
-
Generalized Anxiety Disorder
-
Social Anxiety Disorder (Social Phobia)
-
Panic Attack
-
Obsessive-Compulsive Disorder
Sleep-Wake Disorders
-
Insomnia
-
Substance/Medication Induced Sleep Disorder
Depressive Disorders
-
Bipolar disorders
-
Major Depressive Disorder
-
Persistent Depressive Disorder
Trauma and Stressor Related Disorders
-
Posttraumatic Stress Disorder
-
Acute Stress Disorder
Neurodevelopmental Disorders
-
Autism Spectrum Disorder
-
Attention-Deficit / Hyperactivity Disorder
For many patients suffering from depression, anxiety and insomnia who cannot achieve satisfactory results with medication or are looking for an alternative due to the side effects of medications, NeuroCes™ is an appropriate treatment option.
NeuroCes™ can also be used to help soften the initial transitory adverse effects of pharmaceuticals, such as the activation and jitteriness experienced with some of the selective serotonin reuptake inhibitors (SSRIs).
The Action Mechanisms
01
NeuroCes™ deactivates brain regions associated with overuse consistent with various disorders such as depression, anxiety and insomnia.
02
NeuroCes™ can normalize the balance in functional connectivity of intrinsic neural circuits in the brain.
03
NeuroCes™ increases alpha activity (inducing relaxation and a pleasant state of well-being), decreases delta (increasing attention and alertness) and beta activity (decreasing compulsive thoughts).
04
NeuroCes™ increases the concentration of neurochemicals such as serotonin and noradrenaline and decreases cortisol in the brain which results in improved mood and improved sleep.
NeuroCes™ Cranial Electrotherapy Stimulator has been approved and CE certified as a therapeutic medical device for both clinical use and personal use in the treatment of Depression, Anxiety and Insomnia.
Five meta-analyses were computed in order to summarize most of the studies of Cranial Electrotherapy Stimulation (CES) appearing in the U.S. scientific literature. They are categorized as follows (Smith, 2007):
Safety of NeuroCes™
CES has a foundation of research and clinical use from which proof of safety and effectiveness have been well established. NeuroCes™ is non-invasive and side-effects are mild and self-limiting. Significant side effects or complications attributable to the application of electric current for therapeutic effect are “virtually nonexistent”.
Effective NeuroCes™ Treatment
Following CES treatment, most patients feel less anxious, less distressed, and more focused on mental tasks. Patients with positive outcomes generally sleep better and report improved concentration, increased learning abilities, enhanced recall, and a heightened state of wellbeing after one or a series of CES treatments (Gilula, 2005).
No Placebo Effect
Components of CES administration, including the level of current, pulse width, electrode placement, frequency, waveform, the number of treatments, and duration of treatment, have all been varied without causing injury or preventing positive therapeutic results. Such efficacy in the face of altering so many variables may suggest a placebo effect is responsible for benefit seen with CES; however, multiple double blind studies and animal research has shown that the placebo effect is not responsible for the benefits documented (Kennerly, 2006). No placebo effect in CES treatment has ever been found when that effect was specifically controlled for (Smith, 2007).
The CES device has been proven to inhibit, delay, and reverse the first stages of many neuropsychiatric illnesses. It is also extremely successful in preventing the exacerbation of anxiety, stress, depression, insomnia and rage. Many have found the device helpful in combating problems such as alcohol and drug addiction. It may be the most important breakthrough in electromagnetic field prophylaxis (Smith, 2007).
CE Conformity Statement
NeuroCes™ is an active medical device (Class IIa medical device in accordance with MDD Annex IX – “Classification Criteria” Rule 9) according to Medical Device Directive, which was certified according to ANNEX II (excluding Section IV) of MDD 93/42/EEC by the Notified Body, SIQ.
EN ISO 13485 Certificate
EN ISO 13485 provides a great advantage for NEUROSANTE, the leading innovator and manufacturer of Cranial Electrotherapy Stimulator devices. Our quality system makes our products safe, secure and reliable.
REFERENCES:
(Smith, 2007). Ray B. Smith, Ph. D. Cranial Electrotherapy Stimulation: It’s First Fifty Years, Plus Three: A Monograph. ISBN: 978-1-60247-589-2 & Cranial Electrotherapy Stimulation Lecture.
(Shealy, 1998). Shealy, C. Norman, Cady, Roger K., Culver-Veehoff, Diane, Cox, Richard & Liss, Saul. Cerebralspinal fluid and plasma neurochemicals: response to cranial electrical stimulation. Journal of Neurological and Orthopaedic Medicine and Surgery. 18(2):94-97, 1998.
(Gilula, 2005). Marshall F. Gilula, MD, Daniel L. Kirsch, PhD. Cranial Electrotherapy Stimulation Review: A Safer Alternative to Psychopharmaceuticals in the Treatment of Depression.
(Kennerly, 2006). Kennerly, Richard C. Changes in quantitative EEG and low resolution tomography following cranial electrotherapy stimulation. August 2006, 425 pp., 81 tables, 233 figures, 171 references.